Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Takehiro Inui is active.

Publication


Featured researches published by Takehiro Inui.


Clinical Endocrinology | 1997

Demonstration of fragments with thyroid stimulating activity from Thyroid stimulation blocking antibodies-IgG molecules by papain digestion

Tsuyoshi Kouki; Takehiro Inui; Kei Yamashiro; Takashi Hachiya; Yukio Ochi; Yoshihiro Kajita; Nobuyuki Takasu; Yasushi Sato; Atsuo Nagata

Thyroid stimulation blocking antibodies (TSBAb) inhibit TSH action and may have a role in the pathogenesis of hypothyroidism. In order to study the relationship between blocking and stimulating activities we have examined the biologically active fragments in TSBAb‐IgG molecules after papain digestion.


Hormone Research in Paediatrics | 1999

Clinical Usefulness of TSAb Assay with High Polyethylene Glycol Concentrations

Y. Ochi; Takehiro Inui; Tsuyoshi Kouki; K. Yamashiro; Nobuyuki Takasu; Y. Kajita; Y. Sato; A. Nagata

We previously demonstrated the stimulatory effect of polyethylene glycol (PEG) on thyroid-stimulating antibody (TSAb)-IgG-stimulated cAMP production (thyroid stimulating (TS) index) in porcine thyroid cell (PTC) assay. In the present study the clinical usefulness of the practical method using high PEG concentrations was examined. TS activity using PEG 22.5% precipitated fraction (PF) was significantly higher compared to standard TSAb activity using 12.5% PF from TSAb-positive serum, but the maximum TS activity was observed with PEG 12.5% PF + 4% PEG or PEG 22.5% PF + 2% PEG. In all cases of untreated Graves’ patients, TSAb activity determined by PEG 22.5% PF was higher compared to standard TSAb activity using PEG 12.5% PF from test serum, but the highest TSAb activity was observed by PEG 12.5% PF + 4% PEG without increased cAMP production to normal serum. TSAb was positive in 85% (40/47), 98% (46/47) and 100% (47/47) of untreated Graves’ patients by the method of PEG 12.5% PF, PEG 22.5% PF and PEG 12.5% + 4% PEG, respectively. Increased TSAb activity by PEG 12.5% PF + 4% PEG method was also observed even if the standard TSAb activity using PEG 12.5% PF method was negative in the euthyroid states of Graves’ patients during antithyroid drug therapy. The stimulatory effect of PEG on TS activity was not found in other thyroidal diseases [thyroiditis chronica (with high serum TSH), thyroid stimulation-blocking antibody (TSBAb)-positive sera (with low serum TSH), adenomatous goiter, subacute thyroiditis, and thyroid cancer]. The stimulatory effect of 5% PEG on TS activity produced directly by small amounts of Graves’ serum (50 μl) was also found, although the sensitivity was lower than with PEG-precipitated IgG from 0.2 ml serum. The clinical usefulness of the sensitive TSAb assay using PEG-precipitated IgG or direct serum assay in the presence of high PEG concentrations was demonstrated.


Clinical Endocrinology | 1997

Demonstration of thyroid stimulating activity within H chain fragments of TSAb-IgG by protease digestion and reduction.

Tsuyoshi Kouki; Takehiro Inui; Takashi Hachiya; Hidetoshi Okabe; Yukio Ochi; Yoshihiro Kajita

OBJECTIVE Whether or not the distribution of biologically active fragments in TSAb‐IgG molecules parallels antigen‐binding activity in other anti‐thyroidal antibodies was examined.


Endocrine Research | 1999

Mechanism of the Augmentative Effect of High Polyethylene Glycol (PEG) Concentrations on the Thyroid Stimulating Activity in TSAb-IgG Using a Porcine Thyroid Cell Assay

Kei Yamashiro; Tsuyoshi Kouki; Nobuyuki Takasu; Takehiro Inui; Yukio Ochi; Yoshihiro Kajita; Yasushi Sato; Atsuo Nagata

We previously demonstrated that high polyethylene glycol (PEG) concentrations (5% PEG) significantly augmented cAMP production in response to TSAb-IgG using the porcine thyroid cell (PTC) assay. The mechanism of the stimulatory effect of 5% PEG on cAMP production was examined by a two-step incubation with PTC. TSAb-IgG was preincubated with or without addition of 5% PEG in the PTC assay for 2.5 hr (1st incubation) and separated PTC was re-incubated with fresh Hanks buffer for 5 hr (2nd incubation). cAMP production in the 1st incubation medium by co-incubation of TSAb-IgG and 5% PEG for 2.5 hr was significantly increased (3.3-fold) compared to that without 5% PEG. When the cAMP content in PTC and the incubation medium were compared in the same volume of incubation medium after co-incubation of TSAb-IgG and 5% PEG for 2.5 hr, cAMP contents in PTC were about 7-fold higher than that in the incubation medium, and this ratio did not change in the incubation medium of TSAb-IgG without 5% PEG. Similar increases in cAMP contents in PTC (6.6-fold) compared to the incubation medium were also observed with bTSH, although there was no augmentative effect of 5% PEG on cAMP production by bTSH in either the incubation medium or PTC. When PTC, which had been preincubated with normal-IgG and 5% PEG in the 1st incubation, was re-incubated with TSAb-IgG in the 2nd incubation medium, cAMP production by TSAb-IgG was not stimulated by 5% PEG. The augmentative effect of 5% PEG on cAMP production by TSAb-IgG was observed whenever 5% PEG and TSAb-IgG were co-incubated in either the 1st or 2nd incubation. However, no stimulatory effect of 5% PEG on bTSH was observed. These results suggested the stimulatory effect of 5% PEG on TSAb-IgG-stimulated cAMP production may be due to the increase of binding or incorporation of TSAb-IgG into the membranes of PTC compared to TSH.


Clinica Chimica Acta | 1992

Increased serum concentration of type IV collagen peptide and type III collagen peptide in hyperthyroidism

Takehiro Inui; Yukio Ochi; Wen Chen; Yoshiyuki Nakajima; Yoshihiro Kajita

Serum concentration of type IV collagen peptide, the 7S domain of type IV collagen (type IV collagen 7S) and the amino terminal propeptide of type III procollagen (type III procollagen peptide) is thought to be a useful marker of progressive liver disease. In the present study, serum levels of these collagens in patients with thyroidal diseases with normal liver function were assayed. Increased levels in the hyperthyroid state and relatively decreased levels in the hypothyroid state were observed. The increased levels in hyperthyroidism was most prominent in type IV collagen peptide. The increased level became normal in the subsidence of hyperthyroidism by treatment with anti-thyroid drug. A positive correlation between serum type IV collagen peptide levels and serum thyroid hormone levels such as T4, T3, free T4 and free T3 was observed. These facts show that serum type IV collagen peptide may be influenced by not only liver disease but also serum thyroid hormone levels. Type IV collagen peptide may provide a useful biochemical marker of hyperthyroid state.


Thyroid | 1998

Increase of Thyroid Stimulating Activity in Graves' Immunoglobulin-G by High Polyethylene Glycol Concentrations Using Porcine Thyroid Cell Assay

Takehiro Inui; Tsuyoshi Kouki; Kei Yamashiro; Takashi Hachiya; Yukio Ochi; Yoshihiro Kajita; Yasushi Sato; Atsuo Nagata


Autoimmunity | 1990

Binding of bovine and porcine pituitary glycoprotein hormone alpha-subunit to TSH antibody in serum of patients with Graves' disease.

Yoshihiro Kajita; Yoshiyuki Nakajima; Masao Ishida; Yoichi Fujita; Teruhiko Nagamune; Takashi Hachiya; Masao Nakagawa; Takehiro Inui; Yukio Ochi


Thyroid | 1999

Augmentation of thyroid-stimulating antibody-stimulated cyclic adenosine monophosphate response by polyethylene glycol, polyvinyl alcohol, and dextran; highly sensitive porcine thyroid cell thyroid-stimulating antibody assay.

Kei Yamashiro; Nobuyuki Takasu; Tsuyoshi Kouki; Takehiro Inui; Yukio Ochi; Yoshihiro Kajita; Yasushi Sato; Atsuo Nagata


Thyroid | 1994

Studies on the Action of Thyroid Stimulation Blocking Antibody (TSBAb) on Thyroid Cell Membrane

Wen Chen; Takehiro Inui; Yukio Ochi; Yoshihiro Kajita


Thyroid | 2000

Sensitive Thyroid-Stimulating Antibody Assay in Whole Serum Containing Five Percent Polyethylene Glycol Using Porcine Thyroid Cells

Yukio Ochi; Yoshihiro Kajita; Takehiro Inui; Kei Yamashiro; Nobuyuki Takasu; Yasushi Sato; Atsuo Nagata

Collaboration


Dive into the Takehiro Inui's collaboration.

Top Co-Authors

Avatar

Yoshihiro Kajita

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Yukio Ochi

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Tsuyoshi Kouki

University of the Ryukyus

View shared research outputs
Top Co-Authors

Avatar

Takashi Hachiya

Shiga University of Medical Science

View shared research outputs
Top Co-Authors

Avatar

Kei Yamashiro

Shiga University of Medical Science

View shared research outputs
Top Co-Authors

Avatar

Nobuyuki Takasu

University of the Ryukyus

View shared research outputs
Top Co-Authors

Avatar

Atsuo Nagata

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Hidetoshi Okabe

Shiga University of Medical Science

View shared research outputs
Top Co-Authors

Avatar

Masao Ishida

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Masao Nakagawa

Shiga University of Medical Science

View shared research outputs
Researchain Logo
Decentralizing Knowledge